• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ferrioxamine excretion in iron-loaded man.

作者信息

Pippard M J, Callender S T, Finch C A

出版信息

Blood. 1982 Aug;60(2):288-94.

PMID:7093519
Abstract
摘要

相似文献

1
Ferrioxamine excretion in iron-loaded man.
Blood. 1982 Aug;60(2):288-94.
2
[Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].[去铁胺治疗含铁血黄素沉着症。持续皮下输注期间的粪便铁排泄]
Dtsch Med Wochenschr. 1984 Nov 2;109(44):1682-5. doi: 10.1055/s-2008-1069435.
3
Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
Lancet. 1977 May 7;1(8019):977-9. doi: 10.1016/s0140-6736(77)92279-6.
4
Iron metabolism and iron chelation in the thalassaemia disorders.
Haematologica. 1990 Sep-Oct;75 Suppl 5:66-71.
5
Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.去铁胺和二乙三胺五乙酸联合长期治疗纯合子β地中海贫血中的含铁血黄素沉着症
Ann N Y Acad Sci. 1974;232(0):193-200. doi: 10.1111/j.1749-6632.1974.tb20585.x.
6
Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.成人输血性血色素沉着症患者持续给予去铁胺的评估。
Trans Assoc Am Physicians. 1977;90:335-41.
7
[Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].[铁螯合疗法（去铁胺和抗坏血酸）在血色沉着病和库利贫血中的进一步经验]
Minerva Med. 1978 Mar 17;69(13):811-21.
8
Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.
Ann N Y Acad Sci. 1974;232(0):221-5. doi: 10.1111/j.1749-6632.1974.tb20588.x.
9
[Iron-chelating treatment].
Haematologica. 1989 Oct;74(5 Suppl):241-51.
10
Iron chelating therapy in thalassemia: current problems.地中海贫血的铁螯合疗法：当前问题
Haematologica. 1990 Sep-Oct;75 Suppl 5:84-8.

引用本文的文献

1
A Retrospective Long-Term Study on Age at Menarche and Menstrual Characteristics in 85 Young Women with Transfusion-Dependent β-Thalassemia (TDT).一项关于85名依赖输血的β地中海贫血（TDT）年轻女性初潮年龄和月经特征的回顾性长期研究。
Mediterr J Hematol Infect Dis. 2021 Jul 1;13(1):e2021040. doi: 10.4084/MJHID.2021.040. eCollection 2021.
2
Systemic iron reduction by venesection alters the gut microbiome in patients with haemochromatosis.通过放血进行全身性铁减少可改变血色素沉着症患者的肠道微生物群。
JHEP Rep. 2020 Jul 28;2(6):100154. doi: 10.1016/j.jhepr.2020.100154. eCollection 2020 Dec.
3
β-Thalassemia Intermedia: A Bird's-Eye View.
中间型β地中海贫血：鸟瞰
Turk J Haematol. 2014 Mar;31(1):5-16. doi: 10.4274/Tjh.2014.0032. Epub 2014 Mar 5.
4
Management of the thalassemias.地中海贫血症的治疗管理。
Cold Spring Harb Perspect Med. 2013 Jun 1;3(6):a011767. doi: 10.1101/cshperspect.a011767.
5
Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. timed 非转铁蛋白结合铁测定法在地拉罗司治疗期间探查可螯合铁池的来源，并预测螯合反应。
Haematologica. 2012 Jun;97(6):835-41. doi: 10.3324/haematol.2011.056317. Epub 2011 Dec 16.
6
Ineffective erythropoiesis and thalassemias.无效红细胞生成与地中海贫血。
Curr Opin Hematol. 2009 May;16(3):187-94. doi: 10.1097/MOH.0b013e32832990a4.
7
Regulation of iron absorption in hemoglobinopathies.血红蛋白病中铁吸收的调节。
Curr Mol Med. 2008 Nov;8(7):646-62. doi: 10.2174/156652408786241401.
8
Optimal management strategies for chronic iron overload.慢性铁过载的最佳管理策略。
Drugs. 2007;67(5):685-700. doi: 10.2165/00003495-200767050-00004.
9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.(S)-4,5-二氢-2-(2-羟基-4-羟苯基)-4-甲基-4-噻唑羧酸聚醚：一种解决肾毒性的方法。
J Med Chem. 2006 May 4;49(9):2772-83. doi: 10.1021/jm0508944.
10
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.去铁酮治疗地中海贫血及其他病症铁过载的获益与风险：与去铁胺的流行病学及治疗学方面比较
Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003.